Research programme: NASH therapeutics - La Jolla
Latest Information Update: 18 Jun 2014
At a glance
- Originator La Jolla Pharmaceutical Company
- Developer La Jolla Pharmaceutical Company; Stanford University
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 16 Jun 2014 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO)